

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**阿里健康信息技術有限公司**  
*(incorporated in Bermuda with limited liability)*  
**(Stock Code: 0241)**

**FILING OF NEW LISTING APPLICATION IN RELATION TO VERY  
SUBSTANTIAL ACQUISITION, CONNECTED TRANSACTION AND  
REVERSE TAKEOVER INVOLVING A NEW LISTING APPLICATION**

We refer to the announcement of Alibaba Health Information Technology Limited (the “**Company**”) dated April 15, 2015 (the “**Announcement**”) in relation to, among other things, the Proposed Acquisition. Unless otherwise indicated, capitalized terms defined in the Announcement shall have the same meanings when used herein.

As disclosed in the Announcement, the Proposed Acquisition constitutes a reverse takeover of the Company under Rule 14.06(6)(b) of the Listing Rules. Accordingly, the Company will be treated as if it were a new listing applicant. The Proposed Acquisition is therefore subject to the approval of the Listing Committee of the new listing application made by the Company (the “**New Listing Application**”).

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company filed the New Listing Application with the Stock Exchange on July 2, 2015.

**The Proposed Acquisition is subject to a number of conditions including but not limited to Independent Shareholders’ approval, which may or may not be fulfilled. In addition, the Listing Committee’s approval to the New Listing Application may or may not be granted. In the event that the approval of the New Listing Application is not granted by the Listing Committee, the Agreement will not become unconditional and the Proposed Acquisition will not proceed.**

**Shareholders and potential investors should exercise caution when they deal or contemplate dealing in the Shares or other securities of the Company.**

By Order of the Board  
**Alibaba Health Information Technology Limited**  
**WANG Lei**  
*Chief Executive Officer and Executive Director*

Hong Kong, July 2, 2015

*As at the date of this announcement, the Board comprises nine Directors, of which (i) two are executive Directors, namely Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. ZHANG Yong, Mr. CHEN Jun and Mr. YU Feng; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.*